Literature DB >> 2684518

USA multicenter clinical trial with recombinant human erythropoietin (Amgen). Results in hemodialysis patients.

J W Eschbach1, M R Downing, J C Egrie, J K Browne, J W Adamson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2684518     DOI： 10.1159/000417892

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN： 0302-5144            Impact factor:   1.580


× No keyword cloud information.
  10 in total

1.  Detection of functional iron deficiency during erythropoietin treatment: a new approach.

Authors:  I C Macdougall; I Cavill; B Hulme; B Bain; E McGregor; P McKay; E Sanders; G A Coles; J D Williams
Journal:  BMJ       Date:  1992-01-25

2.  Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm.

Authors:  I C Macdougall; R D Hutton; I Cavill; G A Coles; J D Williams
Journal:  BMJ       Date:  1990-03-10

Review 3.  Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.

Authors:  R Whittington; L B Barradell; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

Review 4.  The use of erythropoietin in renal failure.

Authors:  I C Macdougall; R D Hutton; G A Coles; J D Williams
Journal:  Postgrad Med J       Date:  1991-01       Impact factor: 2.401

5.  Poor response to erythropoietin.

Authors:  I C Macdougall
Journal:  BMJ       Date:  1995-06-03

Review 6.  Safety aspects of parenteral iron in patients with end-stage renal disease.

Authors:  G Sunder-Plassmann; W H Hörl
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

7.  Exercise aggravates cardiovascular risks and mortality in rats with disrupted nitric oxide pathway and treated with recombinant human erythropoietin.

Authors:  Fayçal Meziri; Delphine Binda; Sabeur Touati; Maxime Pellegrin; Alain Berthelot; Rhian M Touyz; Pascal Laurant
Journal:  Eur J Appl Physiol       Date:  2011-01-20       Impact factor: 3.078

Review 8.  Iron, anaemia, and inflammatory bowel diseases.

Authors:  C Gasche; M C E Lomer; I Cavill; G Weiss
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

9.  Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.

Authors:  Jorge F Pérez-Oliva; Martha Casanova-González; Idrian García-García; Pedro J Porrero-Martín; Carmen M Valenzuela-Silva; Tairí Hernández-Montero; Marcia Lagarde-Ampudia; Yuri Casanova-Kutsareva; Yisel Avila-Albuerne; Alicia Vargas-Batista; Hailen Bobillo-López; Raúl Herrera-Valdés; Pedro A López-Saura
Journal:  BMC Nephrol       Date:  2005-05-23       Impact factor: 2.388

10.  Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes.

Authors:  Andreas Schneider; Markus P Schneider; Hubert Scharnagl; Alan G Jardine; Christoph Wanner; Christiane Drechsler
Journal:  BMC Nephrol       Date:  2013-03-22       Impact factor: 2.388
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.